Review of current transfusion therapy and blood banking practices

Storch, Emily K.; Custer, Brian; Jacobs, Michael; Menitove, Jay E.; Mintz, Paul D.

doi:10.1016/j.blre.2019.100593

Cited by 63 publications

(72 citation statements)

References 207 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The current evidence from various randomized clinical trials and meta-analyses support the prophylactic strategy for patients with hematological malignancies receiving chemotherapy and allogeneic hematopoietic stem cell transplantation. 16,[39][40][41][42][43][44][45][46][47] Transfusing platelets in these patients decreases in a significant manner the WHO grade 2 or greater bleeding complications. Stanworth et al 39 conducted a randomized trial that included 600 patients receiving chemotherapy or undergoing HSCT.…”

Section: What Is the Best Platelet Transfusion Strategy: Prophylacticmentioning

confidence: 93%

“…Currently, blood products are leukoreduced at the time of preparation in Spain and other European countries as well as in the USA. 16 High platelet yield have also seen in SDAP as compared to PRD, and also post-transfusion platelet increments have been confirmed to be higher in patients receiving SDAP transfusions. 14,[23][24][25] However, in patients undergoing hematopoietic stem cell transplantation or chemotherapy, Slichter et al 23 found that at doses between 1.1 x 10 11 and 4.4 x 10 11 platelets per square meter, the number of platelets in the prophylactic transfusion had no effect on the incidence of bleeding.…”

Section: Introductionmentioning

confidence: 92%

“…There is quite a variability in platelet threshold recommendations for invasive procedures and surgery according to different current guidelines. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] This is probably due to the lack of scientific evidence available with guidelines, mainly based on expert opinions. The degree of thrombocytopenia is not the only factor associated with bleeding, other factors as hematocrit, coagulation factors and drugs also contribute to the risk of bleeding.…”

Section: What Is the Best Platelet Transfusion Strategy: Prophylacticmentioning

confidence: 99%

“…RDP are considered the standard of care in many centers of Europe, while in the USA up two-thirds to three-quarters of all transfusions given are SDAP. 1,[14][15][16] RDP are obtained from whole-blood collection by the buffy coat method (used commonly in Europe) or from platelet rich plasma (used commonly in the USA). Both RDP and SDAP can be suspended in plasma or in special platelet additive solutions (PAS).…”

Section: Introductionmentioning

confidence: 99%

“…17 The use of PAS reduces the plasma content of platelets to 20% and the expected benefit for patients is the reduction of adverse reactions related to plasma. 16 Among the benefits of transfusing SDAP platelets are decreasing donor exposure and the reduction in septic/infectious and non-infectious platelet transfusion reactions. 14,18 In fact, the RDP units are associated with a 5-6 fold higher risk of bacterial contamination and a twofold higher risk of transfusion transmitted infection (TTI) compared to SDAP.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

<p>Platelet Transfusion: And Update on Challenges and Outcomes</p>

Alcaína¹

2020

JBM

View full text Add to dashboard Cite

Platelet transfusion is a common practice in onco-hematologic patients for preventing or treating hemorrhages. Platelet concentrates can be transfused with therapeutic or prophylactic purposes. With the aim to help clinicians to take the decisions on platelet transfusion, some guidelines have been developed based on the current scientific evidence. However, there are some controversial issues and available scientific evidence is not enough to solve them. There is little information about what is the best platelet product to be transfused: random platelets or single donor apheresis platelets, and plasma-suspended or additive solution suspended platelets. Platelets are often transfused without respecting the ABO compatibility, but influence of this practice on platelet transfusion outcome is not well established. In the prophylactic platelet transfusion set there are some questions unsolved as the platelet threshold to transfuse prior to specific procedures or surgery, and even if platelet transfusion is necessary for some specific procedures as autologous hematopoietic stem cell transplantation. A challenging complication raised from multiple platelet transfusions is the platelet transfusion refractoriness. The study and management of this complication is often disappointing. In summary, although it is a widespread practice, platelet transfusion has still many controversial and unknown issues. The objective of this article is to review the current evidence on platelet transfusion practices, focusing on the controversial issues and challenges.

show abstract

Section: What Is the Best Platelet Transfusion Strategy: Prophylacticmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 92%

Section: What Is the Best Platelet Transfusion Strategy: Prophylacticmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

<p>Platelet Transfusion: And Update on Challenges and Outcomes</p>

Alcaína¹

2020

JBM

View full text Add to dashboard Cite

show abstract

Cryoprotectants for red blood cells: Evaluate safety and effectiveness by in vitro measures

Hu,

Liu,

Ahmad

et al. 2023

MedComm – Future Medicine

View full text Add to dashboard Cite

The transfusion of red blood cells (RBCs) is crucial in current medicinal research. The shelf‐life of donated RBCs preserved by the normal method is very short, limiting their clinical application. Cryopreservation is a reliable and effective technology for the long‐term storage of RBCs. During the process, ice formation will cause irreversible injuries to RBCs. Glycerol is used as a cryoprotectant (CPA) for RBCs to mitigate cryoinjuries. But it severely induces RBC hemolysis and deformation. This review introduces some biocompatible and effective CPAs used for RBC cryopreservation, outlining recent advances. Currently, there is no uniform standard to determine whether a CPA is suitable for RBCs. According to previous studies, we summarize for the first time comprehensive methods to evaluate the performance of CPAs by ensuring their safety and effectiveness. The safety of CPAs is defined as the degree of damage to RBCs, while the effectiveness is demonstrated by the properties of thawed RBCs, including membrane properties, protein activities, rheological properties, and metabolites levels. A novel CPA that is confirmed suitable for RBCs by these methods may be applied to other cells. We believe comprehensive methods can thoroughly evaluate the performance of CPAs and promote the development of transfusion therapy in clinic.

show abstract

Bacteriosynthetic Degradable Tranexamic Acid‐Functionalized Short Fibers for Inhibiting Invisible Hemorrhage

Bao

Zhang

et al. 2023

Small

View full text Add to dashboard Cite

Current research on hemostatic materials have focused on the inhibition of visible hemorrhage, however, invisible hemorrhage is the unavoidable internal bleeding that occurs after trauma or surgery, leading directly to a dramatic drop in hemoglobin and then to anemia and even death. In this study, bacterial nanocellulose (BNC) was synthesized and oxidized from the primary alcohols to carboxyl groups, and then grafted with tranexamic acid through amide bonds to construct degradable nanoscale short fibers (OBNC‐TXA), which rapidly activated the coagulation response. The hemostatic material is made up of nanoscale short fibers that can be constructed into different forms such as emulsions, gels, powders, and sponges to meet different clinical applications. In the hemostatic experiments in vitro, the composites had significantly superior pro‐coagulant properties due to the rapid aggregation of blood cells. In the coagulation experiments with rat tail amputation and liver trauma hemorrhage models, the group treated with OBNC‐TXA1 sponge showed low hemorrhage and inhibited invisible hemorrhage in rectus abdominis muscle defect hemorrhage models, with a rapid recovery of hemoglobin values from 128±5.5 to 165±2.6 g L−1 within 4 days. In conclusion, the degradable short fibers constructed from bacterial nano‐cellulose achieved inhibition of invisible hemorrhage in vivo.

show abstract

Review of current transfusion therapy and blood banking practices

Cited by 63 publications

References 207 publications

<p>Platelet Transfusion: And Update on Challenges and Outcomes</p>

<p>Platelet Transfusion: And Update on Challenges and Outcomes</p>

Cryoprotectants for red blood cells: Evaluate safety and effectiveness by in vitro measures

Bacteriosynthetic Degradable Tranexamic Acid‐Functionalized Short Fibers for Inhibiting Invisible Hemorrhage

Contact Info

Product

Resources

About